Before we had ibrutinib and idelalisib and the other TKIs in the pipelines, for those of us wanting to avoid myelosuppressive therapies, we had HDMP +R.
Dr. Castro and the team at UCSD have championed this therapy and are now moving the bar higher by upgrading to Gazyva as the antibody to the industrial strength steroid in their new clinical trial.
No chemo and you're done in 6 months. There are risks with both meds, but most should be short term.
Please see my blog bkoffman.blogspot.com for my comments and links to the trial itself and the background research.
Admin: Removed brackets around blog URL so that link will work